Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Eukaryotic Gene Expression
Fator do impacto: 2.156 FI de cinco anos: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502

Volumes:
Volume 30, 2020 Volume 29, 2019 Volume 28, 2018 Volume 27, 2017 Volume 26, 2016 Volume 25, 2015 Volume 24, 2014 Volume 23, 2013 Volume 22, 2012 Volume 21, 2011 Volume 20, 2010 Volume 19, 2009 Volume 18, 2008 Volume 17, 2007 Volume 16, 2006 Volume 15, 2005 Volume 14, 2004 Volume 13, 2003 Volume 12, 2002 Volume 11, 2001 Volume 10, 2000 Volume 9, 1999 Volume 8, 1998 Volume 7, 1997 Volume 6, 1996 Volume 5, 1995 Volume 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v22.i4.50
pages 309-324

Integrin Control of Tumor Invasion

Dara S. Missan
Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York, USA
Michael DiPersio
Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York, USA

RESUMO

Metastasis is the leading cause of death in cancer patients, and strategies to inhibit tumor cell invasion are a major focus of current efforts to develop cancer treatments. The extracellular matrix (ECM) provides both structural support and extracellular cues that regulate invasive tumor growth, and tumor-associated changes in ECM contribute to cancer progression. Integrins, the major receptors for cell adhesion to ECM, are important at every stage of cancer and occupy a critical position as transducers of chemical and mechanical signals that control tumor cell responses to ECM (i.e., outside-in signaling), as well as tumor-mediated changes to ECM that facilitate invasive growth and metastasis (i.e., inside-out signaling). Integrins are therefore attractive therapeutic targets for antagonistic agents. Here, we provide an overview of cancer-promoting functions of integrins on tumor cells, with a focus on roles in regulating cell invasion, ECM remodeling, tumor angiogenesis, and gene expression. We will also discuss how integrin functions are modulated by ECM ligands outside the cell, cytoskeletal/signaling proteins inside the cell, and other cell surface proteins. Finally, we will discuss current progress towards developing integrin antagonists for clinical use, including barriers that must still be overcome before integrins can be fully exploited as therapeutic targets.


Articles with similar content:

Cancer Stem Cells, Their Microenvironment and Anoikis
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Sercin Karahüseyinogluc, Sule Ayla
Cell Signaling Pathways Related to Epithelial Mesenchymal Transition in Cancer Metastasis
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Sevinc Inan, Mürvet Hayran
Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Yu Qin, Lynn Gordon, Madhuri Wadehra, Shabnam Mohandessi
Targeting Integrins in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Chiara Pazzagli, Sandra Donnini
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth